创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

罗凌杰, 汤宇翔, 张周朝阳, 梁文华, 谭润琳, 钱威瑾, 王锋. 靶向肿瘤驱动抗原的T细胞受体工程化T细胞治疗策略[J]. 药学进展, 2021, 45(8): 585-596.
引用本文: 罗凌杰, 汤宇翔, 张周朝阳, 梁文华, 谭润琳, 钱威瑾, 王锋. 靶向肿瘤驱动抗原的T细胞受体工程化T细胞治疗策略[J]. 药学进展, 2021, 45(8): 585-596.
LUO Lingjie, TANG Yuxiang, ZHANG-ZHOU zhaoyang, LIANG Wenhua, TAN Runlin, QIAN Weijin, WANG Feng. T Cell Receptor-Engineered T Cells Therapy: Strategy for Targeting Tumor Driver Antigen[J]. Progress in Pharmaceutical Sciences, 2021, 45(8): 585-596.
Citation: LUO Lingjie, TANG Yuxiang, ZHANG-ZHOU zhaoyang, LIANG Wenhua, TAN Runlin, QIAN Weijin, WANG Feng. T Cell Receptor-Engineered T Cells Therapy: Strategy for Targeting Tumor Driver Antigen[J]. Progress in Pharmaceutical Sciences, 2021, 45(8): 585-596.

靶向肿瘤驱动抗原的T细胞受体工程化T细胞治疗策略

T Cell Receptor-Engineered T Cells Therapy: Strategy for Targeting Tumor Driver Antigen

  • 摘要: 肿瘤临床治疗手段日新月异,除临床手术、放射治疗、化学药物治疗和靶向药物治疗外,近年来肿瘤免疫疗法也显示出强大的抗肿瘤疗效,成为肿瘤临床研究的热点之一。基于最近对肿瘤突变抗原的深入研究,一些关键性肿瘤驱动突变抗原以及靶向这些抗原的T细胞得以发现。同时,这些肿瘤驱动突变抗原特异性T细胞高效诱导了抗肿瘤应答,提示了以T细胞-肿瘤驱动突变抗原识别为基础的T细胞受体工程化T细胞(T cell receptor-engineered T cells,TCR-T)肿瘤免疫疗法在肿瘤免疫治疗中的巨大潜力。对近年肿瘤驱动突变抗原与TCR-T肿瘤治疗的研究进展和方法进行综述,以期为TCR-T肿瘤免疫治疗的临床研究提供理论基础。

     

    Abstract: The clinical treatments of tumors have been changing in decades. In addition to such traditional approaches as clinical surgery, radiotherapy, chemotherapy and targeting therapy, tumor immunotherapy has also shown strong anti-tumor efficacy, and has become one of the hot spots in anticancer clinical research. Based on the recent exploration on cancer antigens, several crucial driver mutations and their targeting T cells were identified. Moreover, the driver mutation antigen-specific T cells effectively induced an anti-tumor response,revealing the potential of anti-tumor clinical strategy via T cell receptor-engineered T cell (TCR-T) immunotherapy, which based on the T cell recognition of tumor driver antigens. This paper summarizes the recent progress of tumor driver mutation antigens and the strategy of TCR-T immunotherapy targeting these antigens, so as to provide a theoretical basis for further clinical research on TCR-T tumor immunotherapy.

     

/

返回文章
返回